Amptiv is a biotechnology company that uses a post-transcriptional chemical modification platform to unlock and enhance mRNA performance. By adding a wide range of chemical modifications *after* mRNA synthesis, their system overcomes the limitations of traditional enzymatic production, enabling AI-guided optimization to tune mRNA stability, immunogenicity, and expression for specific therapeutic outcomes.